{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:10:42Z","timestamp":1777597842105,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[1998,12,1]],"date-time":"1998-12-01T00:00:00Z","timestamp":912470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":7696,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1998,12]]},"DOI":"10.1023\/a:1008430515881","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T09:30:06Z","timestamp":1040549406000},"page":"1323-1330","source":"Crossref","is-referenced-by-count":21,"title":["Clinical and pharmacologic phase I study of Cemadotin\u2013HCl  (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer"],"prefix":"10.1016","volume":"9","author":[{"given":"K.","family":"Mross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.H.","family":"Fiebig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Velagapudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.M.","family":"von Broen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008430515881_bb0010","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1021\/np50016a016","article-title":"Marine animal biosynthetic constituents for cancer chemotherapy","volume":"44","author":"Pettit","year":"1981","journal-title":"J Natl Prod"},{"key":"10.1023\/A:1008430515881_bb0015","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1021\/ja00256a070","article-title":"The isolation and structure of a remarkable marine antineoplastic constituent: Dolastatin 10","volume":"109","author":"Pettit","year":"1987","journal-title":"J Am Chem Soc"},{"key":"10.1023\/A:1008430515881_bb0020","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1021\/jo00287a003","article-title":"Isolation and structure of the cytostatic linear depsipeptide Dolastatin 15","volume":"54","author":"Pettit","year":"1989","journal-title":"J Org Chem"},{"key":"10.1023\/A:1008430515881_bb0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/10428199209064902","article-title":"Cytostatic effects of Dolastatin 10 and Dolastatin 15 on human leukemia cell lines","volume":"6","author":"Quentmeier","year":"1992","journal-title":"Leuk Lymph"},{"key":"10.1023\/A:1008430515881_bb0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0145-2126(93)90020-L","article-title":"Effects of dolastatins on human B-lymphocytic leukemia cell lines","volume":"4","author":"Hu","year":"1993","journal-title":"Leuk Res"},{"key":"10.1023\/A:1008430515881_bb0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/jnci\/85.6.483","article-title":"Growth inhibition of human lymphoma cell lines by the marine products, Dolastatins 10 and 15","volume":"84","author":"Beckwith","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008430515881_bb0040","first-page":"36","article-title":"LU103793: Evaluation by human tumor clonogenic assay of a novel dolastatin","volume":"394a","author":"Villalona-Calero","year":"1995","journal-title":"Proc AACR"},{"key":"10.1023\/A:1008430515881_bb0045","first-page":"36","article-title":"Pre-clinical anti-tumor activity of a novel water-soluble Dolastatin 15 analog (LU103793)","volume":"393a","author":"Smith","year":"1995","journal-title":"Proc AACR"},{"key":"10.1023\/A:1008430515881_bb0050","first-page":"394a","article-title":"In vivo anti-tumor activity of LU103793: Evidence for schedule dependency in MX-1. KB3-1 and P388 tumor models","volume":"36","author":"Smith","year":"1995","journal-title":"Proc AACR"},{"key":"10.1023\/A:1008430515881_bb0055","series-title":"Preclinical pharmacology of LU103793, synthetic derivative of dolastatin 15. Proceedings of the 9th NCI-EORTC symposium on new drugs in cancer therapy","author":"Nelson","year":"1996"},{"key":"10.1023\/A:1008430515881_bb0060","first-page":"3085","article-title":"LU103793 (NSC D-669356): A synthetic peptide that interacts with microtubules and inhibits mitosis","volume":"55","author":"De Arruda","year":"1995","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008430515881_bb0065","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00001813-199506000-00005","article-title":"The bcl-2 and p55 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large-cell lymphomas","volume":"6","author":"Maki","year":"1995","journal-title":"Anticancer Drugs"},{"key":"10.1023\/A:1008430515881_bb0070","first-page":"398a","article-title":"Induction of apoptosis in vitro and in vivo by treatment with LU103793","volume":"37","author":"Cocchiaro","year":"1996","journal-title":"Proc AACR"},{"key":"10.1023\/A:1008430515881_bb0075","unstructured":"Hergenrdder S. Effect of amlodipine, trandolapril, nifedipine, clonidine, dihydralazine and prasozin on LU103793 induced changes of cardiovascular parameters after single intravenous administration in anaesthesised dogs. Investigator Brochure, In House Report \u2013 Knoll AG MPF\/HPK 941."},{"key":"10.1023\/A:1008430515881_bb0080","unstructured":"Hege HG, Weymann J. Studies on the metabolism of LU103793 in the dog after single i.v. dosing. Metabolite pattern and structure elucidation of the major metabolites. Investigator Broschure, In House Report \u2013 Knoll AG MPF\/EB 9411."},{"key":"10.1023\/A:1008430515881_bb0085","unstructured":"Barlozzari T. Personal communication."},{"key":"10.1023\/A:1008430515881_bb0090","unstructured":"Blaich G, Halm S, Heimann W. LU103793 \u2013 single dose toxicity study after intravenous administration in the mouse and in the rat. Investigator Broschure, In House Report \u2013 Knoll AG MPF\/ET 9355, 9356."},{"key":"10.1023\/A:1008430515881_bb0095","unstructured":"Fischer A, Heimann W, Jochims K, Neidhardt R. LU103793 \u2013 repeated dose toxicity study (3 treatment cycles) after intravenous administration in beagle dogs. Investigator Broschure, In House Report \u2013 Knoll AG MPF\/ET 9354."},{"issue":"Suppl 1","key":"10.1023\/A:1008430515881_bb0100","first-page":"100","article-title":"Phase I study with the cytostatic peptide LU103793 administered as i.v. bolus injection","volume":"7","author":"Mross","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008430515881_bb0105","first-page":"490","article-title":"Phase I clinical and pharmacokinetic study of LU103793 (Cemadotin Hydrochloride) as an intravenous bolus injection in patients with metastatic solid tumors","volume":"19","author":"Mross","year":"1996","journal-title":"Onkologie"},{"key":"10.1023\/A:1008430515881_bb0110","series-title":"Biopharmaceutics and Clinical Pharmacokinetics","author":"Gibaldi","year":"1991"},{"key":"10.1023\/A:1008430515881_bb0115","series-title":"Pharmacokinetic and Pharmacodynamic Data System for the PC","author":"Heinzel","year":"1993"},{"key":"10.1023\/A:1008430515881_bb0120","first-page":"219","article-title":"Promising new agents under development by the division of cancer treatment, diagnosis, and centers of the National Cancer Institute","volume":"24","author":"Christian","year":"1997","journal-title":"Semin Oncol"},{"issue":"Suppl 5","key":"10.1023\/A:1008430515881_bb0125","first-page":"124","article-title":"Phase I clinical + pharmacokinetic study of the dolastatin analogue LU103793 on a weekly \u00d7 4 schedule","volume":"7","author":"Wolff","year":"1996","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1023\/A:1008430515881_bb0130","first-page":"100","article-title":"LU103793: A phase I study of a novel dolastatin","volume":"7","author":"Villalona-Calero","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008430515881_bb0135","first-page":"428","article-title":"Preclinical pharmacology of the natural marine product Dolastatin 10 (NSC 376128)","volume":"22","author":"Newman","year":"1994","journal-title":"Drug Metab Dispo"},{"key":"10.1023\/A:1008430515881_bb0140","first-page":"15","article-title":"Clinical and pharmacokinetic phase I study with LU103793 administered as 24-hour infusion","volume":"482a","author":"Mross","year":"1996","journal-title":"Proc ASCO"},{"key":"10.1023\/A:1008430515881_bb0145","first-page":"223a","article-title":"Phase I clinical study of LU103793 (cemadotin) given on a weekly (wkly) \u00d7 4 schedule","volume":"16","author":"Wolff","year":"1997","journal-title":"Proc ASCO"},{"key":"10.1023\/A:1008430515881_bb0150","first-page":"223a","article-title":"Phase I and pharmakokinetic (PK) study of LU103793, a water soluble analog of Dolastin 15, on a daily \u00d7 5 schedule","volume":"16","author":"Villalona-Calero","year":"1997","journal-title":"Proc ASCO"},{"key":"10.1023\/A:1008430515881_bb0155","first-page":"223a","article-title":"Phase I trial of Dolastatin-10 in patients with advanced solid tumors","volume":"16","author":"McElroy","year":"1997","journal-title":"Proc ASCO"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419616613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419616613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/9\/12\/1323\/19481553\/9-12-1323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T20:26:58Z","timestamp":1582230418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419616613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1998,12]]}},"alternative-id":["S0923753419616613"],"URL":"https:\/\/doi.org\/10.1023\/a:1008430515881","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1998,12]]}}}